Aeterna Zentaris Inc.

0.1887-0.0032-1.67%Vol 251.11K1Y Perf -78.77%
Jun 24th, 2022 15:59 DELAYED
BID0.1886 ASK0.1900
Open0.1919 Previous Close0.1919
Pre-Market- After-Market0.19
 - -  0.00 0.16%
Target Price
1.50 
Analyst Rating
Strong Buy 1.00
Potential %
694.91 
Finscreener Ranking
★★★★★     64.59
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★★★★+     59.50
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
★★★★+     62.92
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
2.99 
Earnings Rating
Buy
Market Cap22.86M 
Earnings Date
3rd Aug 2022
Alpha-0.01 Standard Deviation0.28
Beta1.65 

Today's Price Range

0.18530.1956

52W Range

0.16450.9750

5 Year PE Ratio Range

-2.9021.90

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
7.58%
1 Month
-7.95%
3 Months
-49.00%
6 Months
-55.07%
1 Year
-78.77%
3 Years
-92.96%
5 Years
-80.34%
10 Years
-99.93%

TickerPriceChg.Chg.%
AEZS0.1887-0.0032-1.67
AAPL141.663.39002.45
GOOG2 370.76117.07005.19
MSFT267.708.84003.41
XOM86.901.69001.98
WFC40.762.86007.55
JNJ182.292.63001.46
FB196.640.99000.51
GE67.083.01004.70
JPM117.323.40002.98
Financial StrengthValueIndustryS&P 500US Markets
11.60
11.80
0.00
0.00
-865.40
Leverage Ratio 1.40
ProfitabilityValueIndustryS&P 500US Markets
97.30
-194.60
-191.70
-710.50
-43.44
RevenueValueIndustryS&P 500US Markets
6.19M
0.05
45.67
26.21
Earnings HistoryEstimateReportedSurprise %
Q01 2022-0.02-0.020.00
Q04 2021-0.02-0.020.00
Q03 2021-0.02-0.0150.00
Q02 2021--0.02-
Q01 2021--0.02-
Q03 2020--0.02-
Q02 2020--0.15-
Q01 2020-0.04-
Earnings Per EndEstimateRevision %Trend
6/2022 QR-0.030.00-
9/2022 QR-0.030.00-
12/2022 FY-0.110.00-
12/2022 FY-0.110.00-
Next Report Date3rd Aug 2022
Estimated EPS Next Report-0.03
Estimates Count1
EPS Growth Next 5 Years %-
Volume Overview
Volume251.11K
Shares Outstanding121.15K
Shares Float121.28M
Trades Count534
Dollar Volume47.94K
Avg. Volume551.42K
Avg. Weekly Volume563.10K
Avg. Monthly Volume503.51K
Avg. Quarterly Volume587.63K

Aeterna Zentaris Inc. (NASDAQ: AEZS) stock closed at 0.1887 per share at the end of the most recent trading day (a -1.67% change compared to the prior day closing price) with a volume of 251.11K shares and market capitalization of 22.86M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 11 people. Aeterna Zentaris Inc. CEO is Klaus Paulini.

The one-year performance of Aeterna Zentaris Inc. stock is -78.77%, while year-to-date (YTD) performance is -46.89%. AEZS stock has a five-year performance of -80.34%. Its 52-week range is between 0.1645 and 0.975, which gives AEZS stock a 52-week price range ratio of 2.99%

Aeterna Zentaris Inc. currently has a PE ratio of -2.60, a price-to-book (PB) ratio of 0.41, a price-to-sale (PS) ratio of 3.44, a price to cashflow ratio of 9.90, a PEG ratio of 2.32, a ROA of -11.69%, a ROC of -16.24% and a ROE of -16.28%. The company’s profit margin is -43.44%, its EBITDA margin is -191.70%, and its revenue ttm is $6.19 Million , which makes it $0.05 revenue per share.

Of the last four earnings reports from Aeterna Zentaris Inc., there were 1 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-0.03 for the next earnings report. Aeterna Zentaris Inc.’s next earnings report date is 03rd Aug 2022.

The consensus rating of Wall Street analysts for Aeterna Zentaris Inc. is Strong Buy (1), with a target price of $1.5, which is +694.91% compared to the current price. The earnings rating for Aeterna Zentaris Inc. stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Aeterna Zentaris Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Aeterna Zentaris Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 33.01, ATR14 : 0.02, CCI20 : 4.80, Chaikin Money Flow : 0.02, MACD : -0.01, Money Flow Index : 63.32, ROC : -0.63, RSI : 41.34, STOCH (14,3) : 68.17, STOCH RSI : 0.89, UO : 53.60, Williams %R : -31.83), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Aeterna Zentaris Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
1 (100.00 %)
1 (100.00 %)
1 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Aeterna Zentaris Inc.

AEterna Zentaris Inc is a biopharmaceutical company commercializing & developing therapeutics & diagnostic tests. The company's product, Macrilen (macimorelin), is the oral test indicated for the diagnosis of adult growth hormone deficiency (GHD). Macrilen is marketed in the U.S. through a license agreement with Novo Nordisk & the company receives royalties on sales. Aeterna owns all rights to macimorelin outside of the U.S. & Canada. It is leveraging the clinical success & safety profile of macimorelin to develop it for the diagnosis of child-onset GHD. The company is actively pursuing opportunities to commercialize macimorelin in the EU & the rest of the world.

CEO: Klaus Paulini

Telephone: +1 843 900-3223

Address: 315 Sigma Drive, Summerville 29486, SC, US

Number of employees: 11

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

65%35%

Bearish Bullish

58%42%

Bearish Bullish

61%39%

TipRanks News for AEZS

News

Stocktwits